Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Key Points. Concurrent APVD was safe and effective in untreated HL without clinically significant treatment delays.CR rates by PET were lower than expected at a

  • 123456 Profile photo of Madelyn

    ASCO23 Plenary Session looking at Nivo-AVD vs. BV-AVD is going to change the landscape for Hodgkin’s Lymphoma. Here are results for a phase II on Pembro-AVD (APVD). We need to move past interim PET and move towards ct-DNA!

    TFOC Takeaways:
    – Incredible PFS at 2 years: 97%
    – Interim PET2 negative: only 57%
    – EOT PET negative: only 87%
    – None of the patients with ct-DNA cleared had relapse regardless of PET results